Back to top
more

Infinity Pharmaceuticals, Inc. (INFI)

(Delayed Data from NSDQ)

$1.71 USD

1.71
99,328

+0.06 (3.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options

Investors need to pay close attention to Infinity Pharmaceuticals (INFI) stock based on the movements in the options market lately.

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

Is the Options Market Predicting a Spike in Infinity (INFI) Stock?

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -6.25% and 11.80%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Momentum Investors Will Love Infinity Pharmaceuticals (INFI)

Does Infinity Pharmaceuticals (INFI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

Implied Volatility Surging for Infinity (INFI) Stock Options

Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.

Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer

Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -6.67% and 130.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.

Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Infinity (INFI) Up 4% Since Last Earnings Report: Can It Continue?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Infinity (INFI) Looks Good: Stock Adds 5.3% in Session

Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.

Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?